Michael W. Flanagan
CIK 1841990 · View on SEC EDGAR ↗
First SEC filing: Feb. 27, 2026 · Latest: Feb. 27, 2026
On this page
Insider transactions
Price change vs current quote, split-adjusted for corporate actions since the filing — not benchmarked, not annualized, not size-weighted
No open-market trades on record; showing all filings.
| Date | Ticker | Code | Shares | Price | Value | Owned after | Δ own | A/D | vs now |
|---|---|---|---|---|---|---|---|---|---|
| Feb. 27, 2026 | RNA | D | 50,000 | — | — | 0 Direct | -100.00% | Disposed | |
| Feb. 27, 2026 | RNA | D | 88,000 | — | — | 0 Direct | -100.00% | Disposed | |
| Feb. 27, 2026 | RNA | D | 72,000 | — | — | 0 Direct | -100.00% | Disposed | |
| Feb. 27, 2026 | RNA | D | 96,000 | — | — | 0 Direct | -100.00% | Disposed | |
| Feb. 27, 2026 | RNA | D | 66,500 | — | — | 0 Direct | -100.00% | Disposed | |
| Feb. 27, 2026 | RNA | D | 25,000 | — | — | 0 Direct | -100.00% | Disposed | |
| Feb. 27, 2026 | RNA | D | 150,365 | — | — | 0 Direct | -100.00% | Disposed | |
| Jan. 20, 2023 | RNA | A | 144,000 | — | — | 144,000 Direct | — | Acquired | |
| Jan. 20, 2023 | RNA | A | 40,000 | — | — | 40,290 Direct | +13793.10% | Acquired | |
| Jan. 21, 2022 | RNA | A | 136,500 | — | — | 136,500 Direct | — | Acquired | |
| Jan. 21, 2021 | RNA | A | 150,000 | — | — | 150,000 Direct | — | Acquired |
P = Open-market purchase · S = Sale · A = Grant/award · M = Option exercise · G = Gift · F = Tax withholding
Insider transactions are not a recommendation; sales are often driven by liquidity or tax reasons.
Derivative holdings (Form 4 Table II)
Options, RSUs and convertible securities reported on Form 4 Table II.
| Date | Ticker | Security | Underlying | Exercise price | Expiration | Shares | A/D |
|---|---|---|---|---|---|---|---|
| Feb. 27, 2026 | RNA | Stock Option (Right to Buy) | Common Stock (50,000) | $31.42 | Jan. 5, 2035 | 50,000 | Disposed |
| Feb. 27, 2026 | RNA | Stock Option (Right to Buy) | Common Stock (88,000) | $10.16 | Jan. 19, 2034 | 88,000 | Disposed |
| Feb. 27, 2026 | RNA | Stock Option (Right to Buy) | Common Stock (72,000) | $6.57 | Sept. 10, 2033 | 72,000 | Disposed |
| Feb. 27, 2026 | RNA | Stock Option (Right to Buy) | Common Stock (96,000) | $22.47 | Jan. 19, 2033 | 96,000 | Disposed |
| Feb. 27, 2026 | RNA | Stock Option (Right to Buy) | Common Stock (66,500) | $14.22 | Jan. 20, 2032 | 66,500 | Disposed |
| Feb. 27, 2026 | RNA | Stock Option (Right to Buy) | Common Stock (25,000) | $26.75 | Jan. 20, 2031 | 25,000 | Disposed |
| Jan. 20, 2023 | RNA | Stock Option (Right to Buy) | Common Stock (144,000) | $22.47 | Jan. 19, 2033 | 144,000 | Acquired |
| Jan. 21, 2022 | RNA | Stock Option (Right to Buy) | Common Stock (136,500) | $14.22 | Jan. 20, 2032 | 136,500 | Acquired |
| Jan. 21, 2021 | RNA | Stock Option (Right to Buy) | Common Stock (150,000) | $26.75 | Jan. 20, 2031 | 150,000 | Acquired |
Exercise/conversion price is blank when not applicable (e.g. RSUs).
Compensation (DEF 14A)
Matched by name from proxy statements (DEF 14A) — verify against the filing.
CIK 1599901
| Fiscal year | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension change | Other | Total |
|---|---|---|---|---|---|---|---|---|
| 2024 | $500,300 | — | $3,315,040 | $632,746 | $337,800 | — | $17,010 | $4,802,896 |
| 2023 | $470,600 | — | $4,210,742 | — | $188,240 | — | $16,379 | $4,885,962 |
| 2022 | $422,000 | — | — | — | $241,400 | — | $15,336 | $2,065,986 |
Figures from the Summary Compensation Table of the company's proxy statement (DEF 14A). Compensation is not a recommendation.